113 related articles for article (PubMed ID: 1450448)
1. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow.
Berger DP; Winterhalter BR; Dengler WA; Fiebig HH
Anticancer Drugs; 1992 Oct; 3(5):531-9. PubMed ID: 1450448
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line.
Pacheco DY; Stratton NK; Gibson NW
Cancer Res; 1989 Sep; 49(18):5108-10. PubMed ID: 2766282
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of toxicity of hepsulfam in human tumor cell lines.
Pacheco DY; Cook C; Hincks JR; Gibson NW
Cancer Res; 1990 Dec; 50(23):7555-8. PubMed ID: 2253204
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.
Marshall MV; Marshall MH; Degen DR; Roodman GD; Kuhn JG; Ross ME; Von Hoff DD
Stem Cells; 1993 Jan; 11(1):62-9. PubMed ID: 8457783
[TBL] [Abstract][Full Text] [Related]
5. Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance.
Armstrong DK; Gordon GB; Hilton J; Streeper RT; Colvin OM; Davidson NE
Cancer Res; 1992 Mar; 52(6):1416-21. PubMed ID: 1540950
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients.
Hincks JR; Adlakha A; Cook CA; Johnson CS; Furmanski P; Gibson NW
Cancer Res; 1990 Dec; 50(23):7559-63. PubMed ID: 2253205
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dimethylaminosulfonates of alkane diols as a novel group of anticancer agents.
Sanyal U; Nanda R; Samanta S; Pain A; Dutta S; Verma AS; Rider BJ; Agrawal KC
Cancer Lett; 2000 Jul; 155(1):89-97. PubMed ID: 10814884
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC
Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848
[TBL] [Abstract][Full Text] [Related]
9. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development.
Fiebig HH; Schmid JR; Bieser W; Henss H; Lohr GW
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):937-48. PubMed ID: 3665999
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo anticancer activity of mitozolomide and sparsomycin in human tumor xenografts, murine tumors and human bone marrow.
Fiebig HH; Berger DP; Köpping K; Ottenheijm HC; Zylicz Z
J Cancer Res Clin Oncol; 1990; 116(6):550-6. PubMed ID: 2254373
[TBL] [Abstract][Full Text] [Related]
11. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening.
Berger DP; Henss H; Winterhalter BR; Fiebig HH
Ann Oncol; 1990 Sep; 1(5):333-41. PubMed ID: 2261375
[TBL] [Abstract][Full Text] [Related]
12. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
[TBL] [Abstract][Full Text] [Related]
13. Hepsulfam induced DNA adducts and its excision repair by bacterial and mammalian 3-methyladenine DNA glycosylases.
Je KH; Son JK; O'Connor TR; Lee CS
Mol Cells; 1998 Dec; 8(6):691-7. PubMed ID: 9895121
[TBL] [Abstract][Full Text] [Related]
14. Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.
Du DL; Volpe DA; Grieshaber CK; Murphy MJ
Invest New Drugs; 1991 May; 9(2):149-57. PubMed ID: 1874599
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical and pharmacokinetic trial of hepsulfam.
Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD
Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887
[TBL] [Abstract][Full Text] [Related]
16. Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.
Marshall MV; Carey KD; Von Hoff DD; Kuhn JG
Invest New Drugs; 1995; 13(1):33-6. PubMed ID: 7499105
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of XK469 (NSC 656889).
LoRusso PM; Parchment R; Demchik L; Knight J; Polin L; Dzubow J; Behrens C; Harrison B; Trainor G; Corbett TH
Invest New Drugs; 1998-1999; 16(4):287-96. PubMed ID: 10426660
[TBL] [Abstract][Full Text] [Related]
19. Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
Roosen N; Doz F; Yeomans KL; Dougherty DV; Rosenblum ML
Cancer Chemother Pharmacol; 1994; 34(5):385-92. PubMed ID: 7520843
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
